Institution · Parent Project Muscular Dystrophy

Most cited papers from Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy

What are the most cited papers from Parent Project Muscular Dystrophy?

The most cited paper from Parent Project Muscular Dystrophy is "A call for transparent reporting to optimize the predictive value of preclinical research" (Story C. Landis et al., 2012), with 1,229 citations. Next come "Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan" (470) and "Airway clearance techniques in neuromuscular disorders: A state of the art review" (335).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 33 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A call for transparent reporting to optimize the predictive value of preclinical research Story C. Landis et al. · Nature Open access	Oct 2012	1,229
2	Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan David J. Birnkrant, Katharine Bushby, Carla Bann et al. · The Lancet Neurology Open access	2 Feb 2018	470
3	Airway clearance techniques in neuromuscular disorders: A state of the art review Michelle Chatwin et al. · Respiratory Medicine Open access	6 Feb 2018	335
4	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy Elizabeth M. McNally et al. · Circulation Open access	4 May 2015	334
5	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Yetrib Hathout et al. · Proceedings of the National Academy of Sciences Open access	26 May 2015	304
6	Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium JOSEPH PATRICK BROWN, Ronald J. Brown · Mutation Research/Genetic Toxicology	Jul 1976	214
7	Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues Annemieke M Aartsma-Rus, Volker W. Straub, Robert James Hemmings et al. · Nucleic Acid Therapeutics Open access	10 Aug 2017	185
8	Reduction of Azo Food Dyes in Cultures ofProteus vulgaris Paul L. Dubin, K. L. Wright · Xenobiotica	1975	153
9	The sarcoglycan complex in limb–girdle muscular dystrophy Leland E. Lim, Kevin P. Campbell · Current Opinion in Neurology	Oct 1998	136
10	Cardiac Management of the Patient With Duchenne Muscular Dystrophy Sujatha Buddhe, Linda H. Cripe, Joshua M. Friedland‐Little et al. · PEDIATRICS Open access	Oct 2018	124
11	Practical Considerations in Using Online Modified-Delphi Approaches to Engage Patients and Other Stakeholders in Clinical Practice Guideline Development Dmitry Khodyakov, Sean Grant, Brian Denger et al. · Patient Open access	23 Sep 2019	116
12	A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy Holly Landrum Peay, Ilene L. Hollin, Ryan A. Fischer et al. · Clinical Therapeutics Open access	May 2014	113
13	Defining patient centricity with patients for patients and caregivers: a collaborative endeavour Guy Yeoman, Patricia Furlong, Michael Seres et al. · BMJ Innovations Open access	24 Mar 2017	105
14	Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey Sophia K. Smith, Wendy K. D. Selig, Matthew J. Harker et al. · PLoS ONE Open access	14 Oct 2015	100
15	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy Volker W. Straub et al. · The Lancet Neurology Open access	6 Jun 2016	96
16	Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Craig M. McDonald et al. · The Lancet Open access	Mar 2022	86
17	DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype Richard T. Wang, Florian Barthélémy, Ann S Martin et al. · Human Mutation Open access	16 Jun 2018	86
18	Photooxidation of milk and milk products: A review Abdus Sattar, John M. deMan, Thomas E. Furia · C R C Critical Reviews in Food Science and Nutrition	Nov 1975	86
19	The analysis of essential oils and extracts (oleoresins) from seasonings ‐ A critical review Uwe‐Jens Salzer, Thomas E. Furia · C R C Critical Reviews in Food Science and Nutrition	Nov 1977	83
20	First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases Laurent Servais, Eric Camino, Aude Clement et al. · Digital Biomarkers Open access	5 Aug 2021	80
21	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy Ronald G. Victor et al. · Neurology Open access	3 Oct 2017	76
22	The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials Diane L. Bloom, Joel Beetsch, Matthew J. Harker et al. · Therapeutic Innovation & Regulatory Science Open access	27 Jul 2017	64
23	Psychosocial Management of the Patient With Duchenne Muscular Dystrophy Mary K. Colvin, James Poysky, Kathi Kinnett et al. · PEDIATRICS	Oct 2018	59
24	Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints Emil Kakkis, Mary O’Donovan, Gerald F. Cox et al. · Orphanet Journal of Rare Diseases Open access	2015	59
25	Exercise and duchenne muscular dystrophy: Where we have been and where we need to go Chad D. Markert, Laura E. Case, Gregory T. Carter et al. · Muscle & Nerve	18 Nov 2011	57
26	Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary Jonathan Daniel Finder, Oscar Henry Mayer, Daniel W. Sheehan et al. · American Journal of Respiratory and Critical Care Medicine	21 Jun 2017	54
27	Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry Leslie Cowen, Maria Laura Mancini, Ann S Martin et al. · BMC Neurology Open access	2 May 2019	53
28	A linearized polynomial mixed integer programming model for the integration of process planning and scheduling Wei Tan, Behrokh Khoshnevis · Journal of Intelligent Manufacturing	13 Aug 2004	53
29	Facioscapulohumeral muscular dystrophy Robin B. Fitzsimons · Current Opinion in Neurology	Oct 1999	52
30	Patient‐centered benefit–risk assessment in duchenne muscular dystrophy Ilene L. Hollin, Holly Landrum Peay, Susan D. Apkon et al. · Muscle & Nerve	20 Sep 2016	47
31	Mothers’ psychological adaptation to Duchenne/Becker muscular dystrophy Holly Landrum Peay, Bettina Meiser, Kathleen Kinnett et al. · European Journal of Human Genetics Open access	26 Aug 2015	47
32	Hydroperoxide destroyers and how they work RICHARD R. HIATT, Thomas E. Furia · C R C Critical Reviews in Food Science and Nutrition	Nov 1975	47
33	Patient and caregiver perspectives on guideline adherence: the case of endocrine and bone health recommendations for Duchenne muscular dystrophy Brian Denger, Kathi Kinnett, Ann S Martin et al. · Orphanet Journal of Rare Diseases Open access	20 Aug 2019	46
34	Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders Holly Landrum Peay, Barbara Bowles Biesecker, Benjamin S. Wilfond et al. · Clinical Trials Open access	23 Feb 2018	46
35	Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis Ilene L. Hollin, Holly Landrum Peay, John F. P. Bridges · Patient	19 Dec 2014	46
36	Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents Holly Landrum Peay, Ryan A. Fischer, Janice Tzeng et al. · PLoS ONE Open access	May 2019	45
37	Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy Annemieke M Aartsma-Rus, Madhuri Hegde, Tawfeg Ben‐Omran et al. · The Journal of Pediatrics ReviewOpen access	19 Dec 2018	45
38	A Transition Toolkit for Duchenne Muscular Dystrophy Christina J. Trout, Laura E. Case, Paula R. Clemens et al. · PEDIATRICS	Oct 2018	45
39	Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy Stephen Lynn, Annemieke M Aartsma-Rus, Kate M. D. Bushby et al. · Neuromuscular Disorders Open access	11 Sep 2014	45
40	How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration Pat Furlong, John F. P. Bridges, Lawrence R. Charnas et al. · Orphanet Journal of Rare Diseases Open access	23 Jun 2015	45
41	Measuring quality of life in muscular dystrophy Carla Bann, Richard Ted Abresch, Barbara Bowles Biesecker et al. · Neurology Open access	7 Feb 2015	44
42	What Elements of an Online Social Networking Profile Predict Target- Rater Agreement in Personality Impressions? David C. Evans, Samuel D. Gosling, Anthony E. Carroll · Proceedings of the International AAAI Conference on Web and Social Media Conference paperOpen access	25 Sep 2021	43
43	Using an Online, Modified Delphi Approach to Engage Patients and Caregivers in Determining the Patient-Centeredness of Duchenne Muscular Dystrophy Care Considerations Dmitry Khodyakov, Sean Grant, Brian Denger et al. · Medical Decision Making Open access	Nov 2019	41
44	The sixth international RASopathies symposium: Precision medicine—From promise to practice Karen Webster Gripp et al. · American Journal of Medical Genetics Part A Open access	11 Dec 2019	40
45	The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management Yanina Jackson, Ellen M. Janssen, Ryan A. Fischer et al. · Expert Review of Pharmacoeconomics & Outcomes Research	9 May 2019	40
46	Progression of Duchenne Cardiomyopathy Presenting with Chest Pain and Troponin Elevation Kan N. Hor, Pace Johnston, Kathi Kinnett et al. · Journal of Neuromuscular Diseases	5 Oct 2017	40
47	Developing a Patient-Centered Benefit-Risk Survey: A Community-Engaged Process Ilene L. Hollin, Caroline Young, Caroline Hanson et al. · Value in Health Open access	Sep 2016	40
48	Transition in Duchenne Muscular Dystrophy: An expert meeting report and description of transition needs in an emergent patient population D.G.M. Schrans, DAVID W. ABBOTT, Holly Landrum Peay et al. · Neuromuscular Disorders	16 Sep 2012	40
49	Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study Norah L. Crossnohere, Ryan A. Fischer, Andrew J. Lloyd et al. · Medical Decision Making	19 Jan 2021	39
50	Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION Chet R. Villa et al. · Pediatric Cardiology Open access	13 Jan 2022	38

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.